StockMarketWire.com - Cell-based therapeutics developer ReNeuron said it had made three appointments to its scientific advisory board.

They included Robert MacLaren, who was a professor of ophthalmology at the University of Oxford, where he directed research into clinical treatments for blindness.

Sally Temple was the scientific director of the Neural Stem Cell Institute in New York, where she led a team of 30 researchers focused on using neural stem cells to develop therapies for eye, brain, and spinal cord disorders.

Jose-Alain Sahel was the chair of the department of ophthalmology at the University of Pittsburgh School of Medicine, and the Eye and Ear Foundation endowed chair of ophthalmology.



Story provided by StockMarketWire.com